statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand...

KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that late-breaking data from the pivotal phase 3 KONFIDENT trial and open label KONFIDENT-S extension trial evaluating the efficacy and...

KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today...

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVistas board of directors granted ten newly-hired employees inducement options to purchase an...

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced its strategic plans for fiscal year 2025, beginning May 1, including for sebetralstat, the Companys investigational novel, oral plasma...

KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year

KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors

KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVistas board of directors granted nine newly-hired employees inducement options to purchase an...

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 1,665,708 shares traded hands during mid-day trading, an increase of...

KalVista Pharmaceuticals (NASDAQ:KALV) Sees Unusually-High Trading Volume

This is a signal that KALV's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

KalVista Pharmaceuticals (KALV, $11.84) RSI Indicator left the oversold zone on March 28, 2024

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.

Watchers	2,418
52-Wk Low	$7.21
52-Wk High	$16.88

Volume	21,035.00
52-Wk High	$16.88
52-Wk Low	$7.21

Period	Estimated	Reported	Surprise	Result
Q4'23	-$0.71	--	--	N/A
Q3'23	-$0.75	-$0.84	-12.42%	MISSED
Q2'23	-$0.76	-$0.80	-4.92%	MISSED
Q1'23	-$0.86	-$0.74	13.75%	BEAT
Q4'22	-$0.87	-$0.77	11.35%	BEAT

KALV KalVista Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals